Tango Therapeutics has demonstrated revenue growth driven by collaborations, particularly with Gilead Sciences, and equity financing fueling its pipeline advancement. Despite significant operating losses, the company maintains a robust cash position that supports operations into 2028. Key assets include multiple precision oncology candidates in early clinical and IND-enabling stages, although regulatory and development risks remain high. Monitoring clinical milestones and capital expenditure will be critical to assessing upcoming inflection points.